A new survey suggests many people with ALS would value even modest slowing of ALS progression as a treatment goal.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with no cure and limited treatment options.

New research from the University of St Andrews, the University of Copenhagen and Drexel University has developed AI ...

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

A look at Amyotrophic Lateral Sclerosis (ALS), focusing on motor neuron degeneration, sporadic versus familial ...

A newly published study says that the body’s own immune system may be responsible for driving the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease. Scientists ...

A recent large study conducted in Sweden has found that long-term exposure to elevated levels of air pollution may increase the risk for the development of motor neuron disease (MND), as well as ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...